Էստոնիա - էստոներեն - Ravimiamet

mcm vaccine b.v. - difteeria toksoid+poliomüeliidi koguviirus, trivalentne, inaktiveeritud+läkaköha tekitaja, puhastatud antigeen+haemophilus influenzae b, konjugeeritud, puhastatud antigeen+hepatiit b viirus, puhastatud antigeen+teetanuse toksoid - süstesuspensioon süstlis - 1annus+1annus+1annus+1annus+1annus+1annus 0.5ml 0.5ml 1tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis serogrupp b fhbp (rekombinantne lipiiditud fhbp (faktor h siduv valk)) alamperekond a; neisseria meningitidis serogrupp b fhbp (rekombinantne lipiiditud fhbp (faktori h siduv valk)) alamperekond b - meningiit, meningokokk - bacterial vaccines, meningococcal vaccines - trumenba on näidustatud 10-aastaste ja vanemate inimeste aktiivseks immuniseerimiseks, et vältida neisseria meningitidis'e serogrupi b poolt põhjustatud invasiivset meningokokki. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Էստոնիա - էստոներեն - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 50ühik 1ml 20ml 1tk; 50ühik 1ml 50ml 1tk; 50ühik 1ml 10ml 1tk

Էստոնիա - էստոներեն - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 25ühik 1ml 20ml 1tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic kasvajad, kastreerimine-vastupidavad - terapeutilised radiofarmatseutilised ühendid - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Էստոնիա - էստոներեն - Ravimiamet

baxalta innovations gmbh - faktor viii inhibiitorist möödamineva aktiivsusega hüübimisfaktorid - infusioonilahuse pulber ja lahusti - 100ühik 1ml 25ml 1tk; 100ühik 1ml 10ml 1tk; 100ühik 1ml 5ml 1tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaktsiinid - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. kasutada shingrix peab olema kooskõlas ametlike soovitustega.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

gsk vaccines s.r.l. - välimine membraan, villid alates neisseria meningitidis 'e grupp b (tüvi nz 98/254), rekombinantse neisseria meningitidis' e grupp b fhbp fusion valk, rekombinantse neisseria meningitidis 'e grupp b nada valk, rekombinantse neisseria meningitidis' e grupp b nhba fusion valk - meningiit, meningokokk - meningokoki vaktsiinid - neisseria meningitidis serogrupi-b tüvede põhjustatud invasiivse haiguse aktiivne immuniseerimine.